These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Elborn JS; Henig NR Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707 [TBL] [Abstract][Full Text] [Related]
45. The role of nebuliser therapy in cystic fibrosis. Geddes D Prof Care Mother Child; 1995; 5(6):147, 149. PubMed ID: 8680235 [No Abstract] [Full Text] [Related]
47. [Antibiotic inhalation in cystic fibrosis. A review of the literature]. Steinkamp G Monatsschr Kinderheilkd; 1991 Feb; 139(2):73-80. PubMed ID: 1903843 [TBL] [Abstract][Full Text] [Related]
48. Inhaled antimicrobial therapy. O'Riordan T; Faris M Respir Care Clin N Am; 1999 Dec; 5(4):617-31. PubMed ID: 10565884 [TBL] [Abstract][Full Text] [Related]
49. Air and soul: the science and application of aerosol therapy. Rubin BK Respir Care; 2010 Jul; 55(7):911-21. PubMed ID: 20587104 [TBL] [Abstract][Full Text] [Related]
51. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Coates AL; Green M; Leung K; Chan J; Ribeiro N; Louca E; Ratjen F; Charron M; Tservistas M; Keller M Pediatr Pulmonol; 2008 Aug; 43(8):753-9. PubMed ID: 18613006 [TBL] [Abstract][Full Text] [Related]
52. Use of high-dose ibuprofen in a pediatric cystic fibrosis center. Fennell PB; Quante J; Wilson K; Boyle M; Strunk R; Ferkol T J Cyst Fibros; 2007 Apr; 6(2):153-8. PubMed ID: 16844429 [TBL] [Abstract][Full Text] [Related]
53. Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis. Mateos-Corral D; Cutz E; Solomon M; Ratjen F Pediatr Pulmonol; 2009 Sep; 44(9):939-40. PubMed ID: 19658112 [TBL] [Abstract][Full Text] [Related]
54. [Cystic fibrosis: current therapy. Inhalation antibiotics]. Mordasini C Schweiz Med Wochenschr Suppl; 2000; 122():43S-44S. PubMed ID: 12536472 [No Abstract] [Full Text] [Related]
55. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542 [TBL] [Abstract][Full Text] [Related]
56. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E; Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983 [TBL] [Abstract][Full Text] [Related]
57. The management of cystic fibrosis. Observations on gentamycin when used with other antibiotics in pulmonary infections associated with cystic fibrosis. Shwachman H; Khaw KT; Kowalski SM Clin Pediatr (Phila); 1975 Dec; 14(12):1115-8. PubMed ID: 1192683 [No Abstract] [Full Text] [Related]
58. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Ryan G; Jahnke N; Remmington T; Smyth A Paediatr Respir Rev; 2013 Mar; 14(1):27-8. PubMed ID: 23228327 [No Abstract] [Full Text] [Related]
59. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Patatanian L Pediatr Infect Dis J; 2006 Mar; 25(3):276-8. PubMed ID: 16511399 [TBL] [Abstract][Full Text] [Related]